GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » PensionAndRetirementBenefit

Lirum Therapeutics (Lirum Therapeutics) PensionAndRetirementBenefit : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics PensionAndRetirementBenefit?

Lirum Therapeutics's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was $0.00 Mil.


Lirum Therapeutics PensionAndRetirementBenefit Historical Data

The historical data trend for Lirum Therapeutics's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics PensionAndRetirementBenefit Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - -

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
PensionAndRetirementBenefit - - - - -

Lirum Therapeutics PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines